title: Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis.
abstract: In 15 patients suffering from maxillofacial cancer with radiochemotherapy-induced oral mucositis the local application of prostaglandin E2 (PGE2) tablets, 0.5 mg four times a day at a 4-h interval was performed. Plasma determination of the bicyclo-prostaglandin E2 metabolite showed no significant amount of the locally applied substance in the circulation. It is claimed that for this particular indication, PGE2 is a potent locally acting compound without affecting circulating levels.
authors.affiliation: University Department of Dentistry, University of Vienna.
authors.forename: M
authors.initials: M
authors.lastname: Matejka
authors.forename: A
authors.initials: A
authors.lastname: Nell
authors.forename: G
authors.initials: G
authors.lastname: Kment
authors.forename: A
authors.initials: A
authors.lastname: Schein
authors.forename: M
authors.initials: M
authors.lastname: Leukauf
authors.forename: H
authors.initials: H
authors.lastname: Porteder
authors.forename: G
authors.initials: G
authors.lastname: Mailath
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D015232:Dinoprostone / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000528:radiation effects*; D011878:Radiotherapy / Q000009:adverse effects; D013280:Stomatitis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D015232:Dinoprostone